In Phase C, individuals will obtain ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or maybe the participants are unable to tolerate the study drugs. 88 These preclinical studies present paradigms for long run clinical trials in https://abbv-744-in-clinical-tria65689.blogunok.com/32312406/little-known-facts-about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers